Language

English
Español
Português
Pусский
Français
Deutsch
日本語
한국어
العربية
Italiano
Nederlands
ελληνικά
Svenska
Polski
ภาษาไทย
Türk
हिंदी
Indonesia
Melayu
Việt

Home

I am a buyer

I am a supplier

Relugolix OR TAK385 ;TAK-385;TAK385 CAS 737789-87-6

1 / 1

Relugolix OR TAK385 ;TAK-385;TAK385 CAS 737789-87-6

Name: Relugolix OR TAK385 ;TAK-385;TAK385 CAS 737789-87-6
Brand: Taizhou Volsen Chemical Co., Ltd.
Rating: 4.7 (4 reviews)

Get Latest Price

Send Inquiry

Model No. :	737789-87-6
Brand Name :	VOLSENCHEM

10yrs

Taizhou, Zhejiang, China

Manufacturer
OEM service

Visit The Store

Gold Supplier
Platform Certification
Online Expo

Taizhou Volsen Chemical Co., Ltd.

VISIT THE STORE

You might also like

1,6-Diazaspiro[3.4]octane, 3-methyl-1-(phenylmethyl)-, ethanedioate (2:1), (3S,4R) Used For Delgocitinib CAS 2230683-29-9

TERT-BUTYL(4R,5R)-4-((E)-4-(4-((TERT-BUTOXYCARBONYL)AMINO)PHENYL)-3-OXOBUT-1-EN-1-YL)-2,2-DIMETHYL- For Vibegron 1426235-01-9

TERT-BUTYL(4R,5R)-4-(4-(4-((TERT-BUTOXYCARBONYL)AMINO)PHENYL)-3-OXOBUTYL)-2,2-DIMETHYL-5-PHENYLOXAZ CAS 1426235-02-0

(6S)-4-OXO-7,8-DIHYDRO-6H-PYRROLO[1,2-a]PYRIMIDINE-6-CARBOXYLIC ACID For Vibegron CAS 1190392-22-3

(1R,2S,3S,4R)-ethyl 3-Aminobicyclo[2.2.2]Octane-2-Carboxylate Hydrochloride CAS 1626482-00-5

3-Pyridazinamine, 6-methoxy- For Relugolix CAS 7252-84-8

Hign Pure Of Relugolix Intermediates 1589503-95-6

Relugolix Intermediate CAS 308831-94-9

Relugolix Intermediate CAS 737789-61-6

Relugolix OR TAK385 ;TAK-385;TAK385 CAS 737789-87-6

Product description

Relugolix CAS number is 737789-87-6, a new drug developed by Myovant and Takeda Pharmaceuticals, is a small molecule gonadotropin releasing hormone (GnRH) receptor antagonist with potential For uterine fibroids, endometriosis, prostate cancer and other indications. Relugolix has been evaluated in nearly 1,600 study participants in Phase 1, Phase 2, and Phase 3 clinical trials. Relugolix can rapidly reduce estrogen and progesterone levels in women when taken orally once daily.
Takeda Pharmaceutical compares the safety and effectiveness of Relugolix CAS 737789-87-6 with leuprorelin in treating menstrual uterine fibrosis through a series of clinical phase III studies in Japan, and the two drugs in the treatment The safety and effectiveness of pain symptoms related to uterine fibrosis finally confirmed the safety and effectiveness of Relugo for uterine fibroids. In addition, Takeda Pharmaceuticals conducted phase II clinical studies of endometriosis and prostate cancer in Relugolix, which confirmed that Relugolix can significantly reduce the pain caused by endometriosis and reduce serum testosterone to castration. Levels and significantly decrease prostate specific antigen (PSA).

Thera. Category: GnRH Receptor Antagonist

Cas No.: 737789-87-6

Synonym:TAK-385;Altropane;Relugolix;TAK-385,Relugolix;RelugolixTAK-385;TKA-385Relugolix;1-[4-[1-[(2,6-difluorophenyl)methyChemicalbookl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;

Molecular Formula: C29H27F2N7O5S

Molecular Weight:623.6303864

Purity: ≥98.%

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

1)Relugolix CAS737789-87-6

2)1-(4-(1-(2,6-difluorobenzyl)-5-(((3-methoxypropyl) (methyl) amino)methyl)-3-(6-methoxy pyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d] pyrimidin-6-yl)phenyl)-3-methoxyurea CAS 737789-61-6

3) ETHYL 2-((2,6-DIFLUOROBENZYL)(ETHOXYCARBONYL)AMINO)-4-METHYL-5-(4-NITROPHENYL)THIOPHENE-3-CARBOXYLA CAS 308831-94-9,

4) 3-Thiophenecarboxylic acid, 2-[[(2,6-difluorophenyl)methyl](ethoxycarbonyl)amino]-4-[(dimethylamino)methyl]-5-(4-nitrophenyl)-CAS 1589503-95-6

5) 3-Pyridazinamine, 6-methoxy- CAS 7252-84-8

Supplier's popular products